Plain-English translation of NCT06495177 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
EUROASPIRE VI is a large European survey looking at how well doctors are managing cardiovascular disease prevention in patients with heart disease or at high risk of developing it. The study examines both people who have already had heart problems and those at high risk due to conditions like high blood pressure, high cholesterol, or diabetes. Researchers will review medical records and conduct interviews to understand current treatment practices and identify ways to improve patient care.
Heart disease remains a leading cause of death in Europe, and this research aims to see whether current medical guidelines are being followed and whether patients are reaching their treatment goals. By understanding real-world practice, doctors can identify gaps and improve how they prevent and manage heart disease.
If you qualify, a researcher will review your medical records and may conduct an interview to gather information about your heart condition, treatments, lifestyle, and how well your current medications are working. Your participation involves sharing your health information and answering questions — typically a one-time visit or phone call. The study runs from 2023 to 2025, and you will not be asked to take any new medications or undergo additional tests beyond your usual care.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
Turkey (Türkiye)
Sponsor
European Society of Cardiology
Collaborators
National Institute for Prevention and Cardiovascular Health, Ireland
Enrollment target
~8,000 participants
Started
June 2024
Primary completion
March 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in August 2026.